Clinical Trials Browser

Phase 2 × Completed × ridaforolimus × Clear all

NCT00770185 2023-08-04

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT00110188 2015-11-20

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Phase 2 Completed

Neoplasms, Prostatic Neoplasms

NCT00736970 2015-08-27

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Phase 2 Completed

Breast Neoplasms

NCT00086125 2015-08-19

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Phase 2 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

NCT00777959 2015-08-19

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Phase 2 Completed

Prostatic Neoplasms

NCT00739830 2015-07-01

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Phase 2 Completed

Endometrial Neoplasms

NCT01010672 2015-04-30

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Phase 2 Completed

Sarcoma

NCT00122343 2015-02-19

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Phase 2 Completed

Neoplasms, Endometrial Neoplasms

NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Phase 2 Completed

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma